We are investigating LogicBio Therapeutics, Inc. (LOGC) (“LogicBio” or the “Company”) for potential violations of the federal securities laws.
On February 10, 2020, LogicBio issued a press release announcing that the U.S. Food and Drug Administration has placed a clinical hold on the Company’s Investigational New Drug submission for its product candidate LB-001 for the treatment of methylmalonic acidemia pending the resolution of certain clinical and nonclinical questions. On this news, LogicBio’s stock price fell $3.34 per share, or 31.96%, to close at $7.11 per share on February 11, 2020.